ASP Isotopes Inc. (NASDAQ:ASPI) Director Robert John Andrew Ryan Buys 9,500 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) Director Robert John Andrew Ryan purchased 9,500 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The stock was bought at an average cost of $3.42 per share, for a total transaction of $32,490.00. Following the purchase, the director now directly owns 546,555 shares in the company, valued at approximately $1,869,218.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ASP Isotopes Trading Down 6.7 %

ASPI stock opened at $3.21 on Tuesday. ASP Isotopes Inc. has a 12-month low of $0.28 and a 12-month high of $4.97. The business’s 50-day moving average is $3.72 and its 200 day moving average is $2.52. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. The stock has a market cap of $157.03 million, a price-to-earnings ratio of -6.55 and a beta of 5.04.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings results on Wednesday, April 10th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.43 million during the quarter. On average, sell-side analysts anticipate that ASP Isotopes Inc. will post -0.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their target price on shares of ASP Isotopes from $5.25 to $5.50 and gave the company a “buy” rating in a research report on Wednesday, April 17th.

Institutional Trading of ASP Isotopes

A hedge fund recently bought a new stake in ASP Isotopes stock. Rathbones Group PLC acquired a new position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 151,750 shares of the company’s stock, valued at approximately $272,000. Rathbones Group PLC owned about 0.31% of ASP Isotopes as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.